Search
NRX Pharmaceuticals Inc
NRXPAdd to Watchlist
3.150USD
+0.030+0.96%
Close 07-31 16:00（ET）Quotes delayed by 15 min
105.43MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of NRX Pharmaceuticals Inc is 8.40, ranking 130 out of 385 in the Biotechnology & Medical Research industry. The average price target is 37.00, with a high of 47.00 and a low of 25.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
40.400
Target Price
+1150.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
NRX Pharmaceuticals Inc
NRXP
5
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is NRX Pharmaceuticals Inc's expected revenue for the next quarter?
NRX Pharmaceuticals Inc's expected revenue is 16.56M.
What is NRX Pharmaceuticals Inc's price target?
Analysts forecast that NRX Pharmaceuticals Inc's price target is USD 37.00, with the highest forecast at USD 47.00 and the lowest forecast at USD 25.00.
How have NRX Pharmaceuticals IncNRXP's recent earnings per share performed?
The market expectation was USD -0.04, while NRX Pharmaceuticals IncNRXP's earnings per share (EPS) for the previous quarter was USD 0.01. EPS for the next quarter is expected at USD 0.06.
What is the analyst rating for NRX Pharmaceuticals Inc?
Based on the ratings of NRX Pharmaceuticals Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.